Hélène Bénédetti
19
Documents
Publications
- 19
- 15
- 15
- 12
- 10
- 9
- 9
- 9
- 9
- 8
- 7
- 6
- 6
- 4
- 4
- 4
- 3
- 3
- 3
- 3
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
LIM kinases, promising but reluctant therapeutic targets: chemistry and preclinical validation in vivoCells, 2022, 11 (13), pp.2090. ⟨10.3390/cells11132090⟩
Article dans une revue
hal-03721458v1
|
|
Design, Synthesis and SAR in 2,4,7-Trisubstituted Pyrido[3,2-d]Pyrimidine Series as Novel PI3K/mTOR InhibitorsMolecules, 2021, 26 (17), pp.5349. ⟨10.3390/molecules26175349⟩
Article dans une revue
hal-03348966v1
|
|
New in-capillary electrophoretic kinase assays to evaluate inhibitors of the PI3k/Akt/mTOR signaling pathwayAnalytical and Bioanalytical Chemistry, 2014, 406 (15), pp.3743-3754. ⟨10.1007/s00216-014-7790-z⟩
Article dans une revue
hal-01180770v1
|
Design, Synthesis, and Biological Activity of Pyridopyrimidine Scaffolds as Novel PI3K/mTOR Dual InhibitorsJournal of Medicinal Chemistry, 2014, 57 (3), pp.613-631. ⟨10.1021/jm401138v⟩
Article dans une revue
hal-01180887v1
|
4-(7H-Pyrrolo[2,3-D]pyrimidin-4-yl)-3,6-dihydropyridine-(2H)-carboxamide derivatives as Limk and/or Rock kinases inhibitors for use in the treatment of cancerFrance, Patent n° : WO2021239727 A1. BCT. 2021
Brevet
hal-03555349v1
|
|
TRISUBSTITUTED PYRIDO[2,3-D]PYRIMIDINES, METHODS FOR PREPARING SAME AND THERAPEUTIC USES THEREOFFrance, Patent n° : WO2014027081. 2014
Brevet
hal-02131560v1
|